Blonanserin

Post Date:
Feb 06,2018
Expiry Date:
Aug 05,2018
Detailed Description:
Cas No. :132810-10-7 Quantity: 100Kilograms
Specs:99%
Payment Method: T/T advance, L/C at sight
Blonanserin (Lonasen) is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
CAS Registry Number:
132810-10-7
Synonyms:
;AD 5423;2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine;2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine;AD-5423;Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-;Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-;2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine;Lonasen;Cycloocta[B]Pyridine, 2-(4-Ethyl-1-Piperazinyl)-4-(4-Fluorophenyl)-5,6,7,8,9,10-Hexahydro-;
Molecular Formula:
C₂₃H₃₀FN₃
Molecular Weight:
367.5028
Molecular Structure:

Offter to Sell